Get started
Author

Thomas Erblich

Observed name: Erblich, T
Observed institutions: St Bartholomew's Hospital, Queen Mary University of London, Barts Health NHS Trust, London Clinic, Hammersmith Hospital, Queen Elizabeth Hospital, Barts Cancer Institute
ORCID: 0009-0008-4911-673X
Observed ORCID: 0009-0008-4911-673X
OpenAlex ID: A5065277141
Clinical outcome of coronavirus disease 2019 in haemato‐oncology patients
2020 · James A. Aries, Jeffrey K. Davies, et al. · British Journal of Haematology · 101
PDF
Venetoclax–based low intensity therapy in molecular failure of NPM1-mutated AML
2023 · Carlos Jimenez-Chillon, Jad Othman, et al. · Blood Advances · 37
Treating relapsed follicular lymphoma
2018 · Thomas Erblich, Silvia Montoto · Expert Review of Hematology · 8
Peripheral blood features of acute myeloid leukemia with myelodysplasia‐related changes developing in a patient with sickle cell anemia
2014 · Sophie Zemenides, Thomas Erblich, et al. · American Journal of Hematology · 8
Pericarditis and Cardiac Tamponade in Patients Treated with First and Second Generation Bruton Tyrosine Kinase Inhibitors: An Underappreciated Risk
2024 · Thomas Erblich, Charlotte Manisty, et al. · Case Reports in Hematology · 5
The complex morphology of acute kidney injury with microangiopathic hemolytic anemia and hyposplenism
2015 · Thomas Erblich, Peter D. Hill, et al. · American Journal of Hematology · 3
A Novel Approach: Nanopore Sequencing of Native Cell-Free DNA in Diffuse-Large B-Cell Lymphoma Patients
2023 · Thomas Erblich, Carolin Sauer, et al. · Blood · 2
Cardiac toxicities of Bruton’s tyrosine kinase inhibitors: The risk of pericarditis and cardiac tamponade
2024 · Thomas Erblich · Journal of Clinical and Experimental Hematology · 1
PDF
Exploratory Analysis and Classification of Lymphoma DNA Methylation Data
2026 · Maria-Iuliana Bocicor, Thomas Erblich · Communications in computer and information science
Works count: 12
Citation count: 164
H-index: 5
I10-index: 2
Year
Topic
Type